莉芙敏片联合戊酸雌二醇和黄体酮治疗围绝经期综合征的疗效观察

Clinical observation of Remifemin Tablets combined with estradiol valerate and progesterone in treatment of perimenopausal syndrome

目的观察莉芙敏片联合戊酸雌二醇片和黄体酮胶囊治疗围绝经期综合征的临床疗效。方法选取2013年6月—2015年6月屯昌县人民医院妇科收治的围绝经期综合征患者88例,按不同治疗方案分为治疗组和对照组,每组各44例。对照组口服戊酸雌二醇片,1 mg/次,1次/d,治疗一个月后开始服用黄体酮胶囊,2粒/次,1次/d。治疗组在对照组用药基础上给予莉芙敏片,1片/次,2次/d。两组患者均治疗3个月。观察两组的临床疗效,同时比较两组患者治疗前后的Kupperman指数(KMI)评分、阴道萎缩症状评分、促卵泡生成素(FSH)及雌二醇(E2)水平。结果治疗后,对照组和治疗组的总有效率分别为86.36%、93.73%,两组总有效率比较差异有统计学意义(P<0.05)。治疗后,两组患者潮热汗出、感觉异常、失眠、抑郁、皮肤瘙痒、骨关节痛评分及KMI总评分均显著降低,同组治疗前后差异具有统计学意义(P<0.05);且治疗组这些观察指标明显优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者阴道干涩、阴道瘙痒、性交痛评分及阴道萎缩症状总评分均显著降低,同组治疗前后差异具有统计学意义(P<0.05);且治疗组这些观察指标明显好于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者FSH显著降低,和E2显著升高,同组治疗前后差异具有统计学意义(P<0.05);且治疗组这些观察指标的改善程度优于对照组,两组比较差异具有统计学意义(P<0.05)。结论莉芙敏片联合戊酸雌二醇片和黄体酮胶囊治疗围绝经期综合征的疗效显著,可以改善患者血清FSH和E2水平,不良反应少,具有一定的临床推广应用价值。

Objective To observe the clinical effect of Remifemin Tablets combined with Estradiol Valerate Tablets and Progesterone Capsules in treatment of perimenopausal syndrome. Methods Patients （88 cases） with perimenopausal syndrome in Tunchang People＇s Hospital from June 2013 to June 2015 were enrolled in this study. According to the different treatment plan, patients were divided into control and treatment groups, and each group had 44 cases. The patients in the control group were po administered with Estradiol Valerate Tablets, 1 mg/time, once daily. After treatment for one month, the patients were po administered with Progesterone Capsules, 2 grains/times, once daily. The patients in the treatment group were po administered with Remifemin Tablets on the basis of control group, 1 tablet/time, twice daily. The patients in two groups were treated for three months. After treatment, clinical efficacy was evaluated, and KMI scores, vaginal atrophy symptom scores, and levels of FSH and E2 in two groups were compared before and after treatment. Results After treatment, the efficacies in the control and treatment groups were 86.36% and 93.73%, respectively, and there was significant difference between groups （P 〈 0.05）. After treatment, the scores of hot flushes and sweating, paresthesia, insomnia, depression, itchy skin, and joint pain, and total KMI score in two groups were significantly decreased, and the difference was statistically significant in the same group （P 〈 0.05）. And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups （P 〈 0.05）. After treatment, the scores of colpoxerosis, itchy vaginal, intercourse pain, and vaginal atrophy symptom in two groups were significantly decreased, and the difference was statistically significant in the same group （P 〈 0.05）. And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups （P 〈 0.05）. After treatment, the FSH in two groups was significantly decreased, but the E2 in two groups were significantly increased, and the difference was statistically significant in the same group （P 〈0.05）. And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups （P 〈 0.05）. Conclusion Remifemin Tablets combined with Estradiol Valerate Tablets and Progesterone Capsules has clinical curative effect in the treatment of perimenopausal syndrome, and can improve the levels of FSH and E2 in patients, and less adverse reactions, which has a certain clinical application value.